Engineering lipid-coated silica nanoparticles as versatile adjuvant delivery platform for the TLR4 agonist MPLA

Key Points

• Enhanced immune response was observed with lipid-coated silica nanoparticles delivering MPLA effectively.
• The analysis showed a notable increase in immune activation levels, highlighting a robust immune response.
• Engineering of lipid-coated silica nanoparticles was utilized to improve adjuvant delivery for TLR4 agonist MPLA.
• This technology may enable more effective vaccine development, but further studies are needed for clinical application.